Dr. Amanda Cashen, MD

About Amanda Cashen, MD

Education:

• MD from Washington University School of Medicine, 2015.

Experience:

• Completed Residency in Internal Medicine at Barnes-Jewish Hospital/Washington University School of Medicine, 2018.
• Finished Fellowship in Hematology and Oncology at Washington University School of Medicine, 2021.
• Serving as an Assistant Professor of Medicine at Washington University School of Medicine since 2023.

Area of expertise

Affiliated Hospitals

Washington University School Of Medicine

Siteman Cancer Center At West County Hospital

Clinical Trials Amanda Cashen, MD is currently running

CIML NK Cell Therapy

for Acute Myeloid Leukemia

This is a standard phase 2 study powered to demonstrate improvement in the 100 day leukemia free survival to 30% from \<10% expected with the use of reduced intensity haplo-HCT in this extremely high-risk patient cohort (based on the institutional experience using non-myeloablative / reduced intensity conditioning in a similar patient cohort). A formal safety evaluation will be done after every 6th patient enrolled and the trial will be stopped if noted to have unusually higher engraftment failure (acute GVHD rates (\>60% any grades or \>30% grade III/IV or ≥ 50% severe cGVHD) or engraftment failure rates (≥15%).

Recruiting1 award Phase 2

Memory-like NK Cell Therapy

for Acute Myeloid Leukemia

Donor Lymphocyte Infusion (DLI) following salvage chemotherapy is the one of the most widely used treatment approaches in patients who relapse after allogeneic hematopoietic cell transplant (allo-HCT). However, the complete remission (CR) rates and long term survival remain very poor in these patients and, therefore, there is an unmet need to develop more effective treatment approaches in patients who relapse after allo-HCT. Based on the initial promising results with our ongoing cytokine-induced memory-like (CIML) natural killer (NK) cell trial, the investigators hypothesize that combining the CIML NK cells with DLI approach will significantly enhance the graft versus leukemia and therefore potentially provide potentially curative therapy for these patients with otherwise extremely poor prognosis. Combining CIML NK cells with the DLI platform will also potentially allow these adoptively transferred cells to persist for longer duration as they should not be rejected by donor T cells as the CIML NK cells are derived from the same donor. The use of CIML NK cells is unlikely to lead to excessive graft versus host disease (GVHD) as previous studies have not been associated with excessive GVHD rates.

Recruiting1 award Phase 1 & 2

More about Amanda Cashen, MD

Other Doctors you might be interested in

Frequently asked questions